在心力衰竭中符合4个药理学支柱的资格,在出院时减少射出分数
Domenico D'Amario1, Daniele Rodolico2, Agni Delvinioti3
1Department of Translational Medicine Università del Piemonte Orientale Novara Italy.
Journal of the American Heart Association
|June 29, 2023
概括
发起心力衰竭 (HF) 的四重治疗,在出院时减少排气分数 (HFrEF) 是可行的,并可能减少重新住院. 功能障碍是实施这种基于证据的治疗策略的关键障碍.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据.
背景情况:
- 目前的指导方针主张在心力衰竭中使用多种药物治疗,减少喷射率 (HFrEF).
- 有限的现实世界的数据存在于同时启动四个基础的药理疗法在医院出院后脱补偿.
- 了解处理模式和障碍对于优化HFrEF管理至关重要.
研究的目的:
- 评估启动HFrEF患者在出院时四重治疗的现实可行性和影响.
- 确定基本药物处方数量的预测因素和早期再入院的风险.
- 评估HFrEF中指南导向医疗治疗的禁忌的流行率.
主要方法:
- 现实世界数据市场的回顾性分析,包括被诊断为心力衰竭的患者.
- 选择连续的HFrEF患者 (排泄分数<40%) 在首次HF住院后出院.
- 基于出院药物的分类,对禁忌的评估和治疗强度和再住院风险预测指标的后勤回归.
主要成果:
- 近一半 (49.2%) 的HFrEF患者在出院时接受了指导方针推的两种药物.
- 虽然β-阻塞剂 (93.4%) 和氨酸- ангиотензин系统抑制剂/ ангиотензин受体- 尼普利辛抑制剂 (68.2%) 是常见的,但矿物质皮质类受体对抗剂 (32.5%) 和-葡萄糖携带载体2抑制剂 (潜在处方在71.1%) 的利用率较低.
- 四重疗法在46.2%的患者中是可能实施的;功能障碍是接受少于两种基础药物的显著预测因素.
- 处方两种或更多的基础药物与30天再入院的风险较低有关.
结论:
- 在大量患者中,可在出院时同时启动HFrEF的四倍疗法.
- 实施四重疗法可能会带来预后益处,包括降低再住院率.
- 功能障碍成为主要的临床因素,限制了在这个现实世界队列中实施全面的指导方针导向医学治疗.
更多相关视频
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.5K
05:15Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
138
相关概念视频
01:30Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
01:30Heart Failure IV: Classification and Diagnostic Evaluation
20
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
20
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:17Pathophysiology of Heart Failure
1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16